Annexin A1 in primary tumors promotes melanoma dissemination

Boudhraa, Zied; Rondepierre, Fabien; Ouchchane, Lemlih; Kintossou, Roselyne; Trzeciakiewicz, Anna; Franck, F.; Kanitakis, Jean; Labeille, B.; Joubert‐Zakeyh, Juliette; Bouchon, Bernadette; Perrot, Jean; Mansard, Sandrine; Papon, Janine; Déchelotte, P.; Chezal, Jean‐Michel; Miot-Noirault, Élisabeth; Bonnet, Mathilde; D’Incan, M.; Degoul, Françoise

doi:10.1007/s10585-014-9665-2

Cited by 45 publications

(36 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports suggest that ANXA1 is involved in membrane aggregation, cell matrix interaction, vesicle transport, phagocytosis, proliferation, apoptosis, inflammation and cell transformation29. ANXA1 expression is up-regulated in breast cancer30, hepatocellular carcinoma31, melanoma32, and rectal cancer, but down regulated in nasopharyngeal carcinoma33 and cervical cancer34. In breast cancer, ANXA1 expression is associated with BRCA1/2 mutations35.…”

Section: Discussionmentioning

confidence: 99%

Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach

Wang

Zhi

Liu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to identify biomarkers for gastric cancer (GC) by iTRAQ. Using proteins extracted from a panel of 4 pairs of gastric adenocarcinoma samples (stage III-IV, Her-2 negative), we identified 10 up regulated and 9 down regulated proteins in all four pairs of GC samples compared to adjacent normal gastric tissue. The up regulated proteins are mainly involved in cell motility, while the down regulated proteins are mitochondrial enzymes involved in energy metabolism. The expression of three up regulated proteins (ANXA1, NNMT, fibulin-5) and one of the down regulated proteins (UQCRC1) was validated by Western Blot in 97 GC samples. ANXA1 was up regulated in 61.36% of stage I/II GC samples compared to matched adjacent normal gastric tissue, and its expression increased further in stage III/IV samples. Knockdown of ANXA1 by siRNA significantly inhibited GC cell migration and invasion, whereas over expression of ANXA1 promoted migration and invasion. We found decreased expression of UQCRC1 in all stages of GC samples. Our data suggest that increased cell motility and decreased mitochondrial energy metabolism are important hallmarks during the development of GC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach

Wang

Zhi

Liu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Recent studies have reported that ANXA1 may function as either a negative or a positive regulator of malignant phenotypes of various cancer cells. For example, downregulation of ANXA1 expression with specific ANXA1 siRNA in human breast cancer cell line MDA-MB-231 led to decreased cancer cell migration and invasion [10]; Ang et al [25] observed that silencing of ANXA1 with specific ANXA1 siRNA could reverse the estrogen-dependent proliferation as well as growth arrest of MCF-7 breast cancer cells; Boudhraa et al [9] reported that in a B16Bl6 spontaneous metastasis model, a siRNAinduced decrease in tumoral ANXA1 expression significantly reduced tumoral MMP2 activity and number of lung metastases, and in human melanoma cell lines, ANXA1 Fig. 3 Relative expression of annexin A1 (ANXA1) protein in hepatocellular carcinoma (HCC) cell lines HepG2 and BEL-7402 transfected with ANXA1 siRNA (si-ANXA1) and negative control siRNA (si-con).…”

Section: Discussionmentioning

confidence: 99%

“…Growing evidence suggest that it contributes to the pathological consequence and sequelae of most serious human diseases, including cancers. As a potential marker for malignant progression, ANXA1 expression levels have been observed to be upregulated in melanoma, breast cancer, pancreatic cancer, and colorectal cancer [9][10][11][12][13]. In contrast, reduced ANXA1 expression levels have been found in esophageal cancer, gastric cancer, bile duct cancer, and prostate cancer [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype

Lin

Fang

et al. 2014

Med Oncol

View full text Add to dashboard Cite

Annexin A1 (ANXA1) belongs to the annexin superfamily of proteins, which contribute to the pathological consequence and sequelae of most serious human diseases. Recent studies have reported diverse roles of ANXA1 in various human cancers; however, its involvement in human hepatocellular carcinoma (HCC) still remains controversial. To investigate the expression pattern of ANXA1 in HCC tissues and evaluate its associations with tumor progression and patients' prognosis, immunohistochemistry was performed using 160 pairs of formalin-fixed and paraffin-embedded cancerous and adjacent non-cancerous tissues from patients with HCC. Then, the associations between ANXA1 expression, clinicopathological characteristics, and prognosis of HCC patients were statistically evaluated. In vitro migration and invasion assays of siRNA-targeted ANXA1-transfected cells were further performed. As a result, the expression levels of ANXA1 protein in HCC tissues were significantly higher than those in adjacent non-cancerous tissues (P < 0.001). High ANXA1 expression was closely correlated with advanced TNM stage (P = 0.001) and high Edmondson grade (P = 0.02). Then, univariate and multivariate analyses showed that the status of ANXA1 expression was an independent predictor for overall survival of HCC patients. Furthermore, knockdown of ANXA1 by transfection of siRNA-ANXA1 could suppress the migration and invasion abilities of HCC cells in vitro. Collectively, these findings offer the convincing evidence that ANXA1 may play an important role in HCC progression and can be used as a molecular marker to predict prognosis and a potential target for therapeutic intervention of HCC.

show abstract

“…A increasing number of studies suggested that the expression and the function of ANXA1 in tumors are tissue-and tumor-specific (9,10). Upregulation of ANXA1 was observed in human breast cancer (11), hepatocellular carcinoma (12) and melanoma (13,14), whereas downregulation of ANXA1 was observed in gastric cancer (15), prostate cancer (16,17) and oral cancer (18,19). The function of ANXA1 in tumors appears to be paradoxical.…”

Section: Introductionmentioning

confidence: 99%

ANXA1 affects cell proliferation, invasion and epithelial‑mesenchymal transition of oral squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Annexin A1 (ANXA1) acts either as a tumor suppressor or an oncogene in different tumor types. Several clinical studies revealed that the expression of ANXA1 is associated with the pathologic differentiation grade in oral squamous cell carcinoma (OSCC) patients. However, the direct function of ANXA1 in OSCC progression has remained to be fully clarified. The present study was designed to investigate the role of ANXA1 in OSCC cell proliferation and invasion in vitro. Furthermore, whether ANXA1 was involved in transforming growth factor β1 (TGFβ1)/epidermal growth factor (EGF)-induced epithelial-mesenchymal transition (EMT) in OSCC was explored. Tca-8113 and SCC-9 cells were transfected with ANXA1-pcDNA3.1 plasmid to overexpress ANXA1. Subsequently, cell proliferation and invasion were examined using MTT and Transwell-Matrigel invasion assays. TGFβ1 and EGF were used to induce EMT in Tca-8113 and SCC-9 cells, and the expression of epithelial (E)-cadherin, neural (N)-cadherin and vimentin was determined by western blot analysis. The results demonstrated that ANXA1 overexpression induced a significant decrease of cell growth and invasiveness in Tca-8113 and SCC-9 cells. The expression of E-cadherin was significantly increased, while the expression of vimentin and N-cadherin was significantly decreased in ANXA1-overexpressing Tca-8113 and SCC-9 cells. ANXA1 expression was significantly decreased in TGFβ1/EGF-treated cells. Furthermore TGFβ1/EGF-induced EMT in OSCC cell lines was attenuated by ANXA1 overexpression. In conclusion, to the best of our knowledge, the present study was the first to evidence that ANXA1 inhibits OSCC cell proliferation and invasion in vitro. TGFβ1/EGF-induced EMT was reversed by ANXA1 in OSCC. ANXA1 was suggested to be a potential marker for OSCC as well as a novel treatment.

show abstract

Annexin A1 in primary tumors promotes melanoma dissemination

Cited by 45 publications

References 56 publications

Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach

Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach

Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype

ANXA1 affects cell proliferation, invasion and epithelial‑mesenchymal transition of oral squamous cell carcinoma

Contact Info

Product

Resources

About